# UNIVERSITY OF COLORADO DENVER: Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | UNIVERSITY OF COLORADO DENVER |
| Location | Aurora, CO |
| Project | Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer |
| Project number | 4R01CA288651-03 |
| Mechanism | R01 |
| Institute | National Cancer Institute |
| Award | $1,201,333 |
| Awarded | 2026-09-07 |
| Project period | 2024-09-01 to 2029-08-31 |
| UEI | MW8JHK6ZYEX8 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11398114). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.